Safety and effectiveness of a 2009 H1N1 vaccine in chronic kidney disease children

Nephron Clin Pract. 2014;128(3-4):341-4. doi: 10.1159/000368410. Epub 2014 Dec 19.

Abstract

Background/aims: Influenza vaccination is the most effective method for preventing influenza infection and its complications. The risk groups are children with chronic kidney diseases (CKDs) such as children on peritoneal dialysis (PD) and hemodialysis (HD), predialysis CKD (pCKD) and renal transplant (RTx) patients and immunosuppressed children. The aim of the present study was to assess the safety and immunogenicity of a single administration of a monovalent inactivated pandemic (H1N1) 2009 vaccine in children with CKD.

Methods: Patients were given a single intramuscular injection of 0.5 ml of monovalent inactivated vaccine.

Results: Totally, there were 25 pediatric patients with a diagnosis of CKD (16 PD, 2 HD, 3 pCKD and 4 RTx). Seroconversion was observed in 15 of the 16 patients with PD. Seroconversion occurred in all patients undergoing pCKD and HD. However, 3 of the RTx patients were seronegative.

Conclusion: This study demonstrated a high level of immunogenicity and safety of an (H1N1) 2009 influenza vaccine in children with CKD.

MeSH terms

  • Adolescent
  • Child
  • Female
  • Humans
  • Immunocompromised Host*
  • Immunosuppressive Agents / administration & dosage
  • Influenza A Virus, H1N1 Subtype
  • Influenza Vaccines / immunology*
  • Influenza, Human / prevention & control*
  • Male
  • Renal Dialysis*
  • Renal Insufficiency, Chronic / complications*
  • Renal Insufficiency, Chronic / therapy*
  • Turkey
  • Young Adult

Substances

  • Immunosuppressive Agents
  • Influenza Vaccines